Checkpoint Therapeutics, Inc. (CKPT)
- Previous Close
1.6700 - Open
1.6800 - Bid 1.5800 x 200
- Ask 1.6100 x 300
- Day's Range
1.5900 - 1.7216 - 52 Week Range
1.3000 - 3.6200 - Volume
469,359 - Avg. Volume
496,425 - Market Cap (intraday)
57.098M - Beta (5Y Monthly) 0.93
- PE Ratio (TTM)
-- - EPS (TTM)
-3.1700 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
17.25
Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is also developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
checkpointtx.comRecent News: CKPT
Performance Overview: CKPT
Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CKPT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CKPT
Valuation Measures
Market Cap
56.74M
Enterprise Value
51.81M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
289.33
Price/Book (mrq)
--
Enterprise Value/Revenue
503.04
Enterprise Value/EBITDA
-0.99
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-349.18%
Return on Equity (ttm)
--
Revenue (ttm)
103k
Net Income Avi to Common (ttm)
-51.85M
Diluted EPS (ttm)
-3.1700
Balance Sheet and Cash Flow
Total Cash (mrq)
4.93M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-43.27M